小学生接种痘苗病毒重组乙肝疫苗的现场试验  

A community trial of vaccinia recombinant hepatitis B vaccine in chil-dren

作　　者：徐德忠[1] 肖乐义 王淑珍[1] 符大卫 闫永平 陈友绩 徐江淮 韩雅儒[1] 

机构地区：[1]北京生物制品研究所

出　　处：《第四军医大学学报》1995年第1期31-33,共3页Journal of the Fourth Military Medical University

摘　　要：作者报告了西安市８６名易感的小学生接种痘苗病毒重组乙肝疫苗一年的效果观察结果。受试者随机分成３组，免疫剂量分别为２．０，５．０，１０．０μｇ，按０，１，６程序接种。结果表明，免疫后６个月各组的抗－ＨＢｓ应答率均达９６％以上；低应答率为１．２％（１／８１）．３个组免疫后６个月与１２个月的抗－ＨＢｓ几何平均滴度分别为２３９．１，２９４．７，２４１．０ｍＩＵ／ｍｌ与２３５．１，３４９．３，３３５．６ｍＩＵ／ｍｌ，３组之间均无明显差异（Ｐ＞０．０５）．与文献比较提示，本实验疫苗的免疫原性良好，５．０μｇ与１０．０μｇ组的抗－ＨＢｓ在免疫后３年将能保持较高水平。因此，痘苗重组乙肝疫苗以５．０或１０．０μｇ剂量免疫为宜。In this paper,the authors reported on the effects of vaccinia recombinant hepatitis B vaccine oneyear following vaccination in 86 susceptible children of Xi’an,The subjects were randomly divided into 3groups and were innoculated by the procedure of 0,1, 6 and at the dose of 2.5,5.0 and 10. 0μg, respective-ly.The findings showed that the anti-HBs response rate in the 3 groups was above 96%6months after im-munization and the poor-response frequency was 1.2%(1/81 The geomatric mean titer(GMT)of anti-HBs in 2.5,5. 0 and 10. 0 μg groups was 231, 294.7 and 241.0 mIU/ml, and 235.1, 349. 3 and 335.6mIU/ml 6 and 12 months after vaccination, respectively. No significant difference was observed among the 3groups.The results of the present study and previous studies suggested that the vaccinia recombinant hepati-tis B vaccine possessed reliable immunogenecity, and higher anti-HBs titers were maintained in 5.0 and 10.0μg groups 3 years after immunization;therefore the optimal dose of the vaccine may be either 5. 0 μg or 10.0μg.

关 键 词：乙型肝炎 疫苗 痘苗病毒 重组 

分 类 号：R512.620.1[医药卫生—内科学]